Myelofibrosis (MF) is characterized by hyperactivation of thrombopoietin (TPO) signaling, which induces a RPS14 deficiency that de-regulates GATA1 in megakaryocytes by hampering its mRNA translation. As mice carrying the hypomorphic Gata1 low mutation, which reduces the levels of Gata1 mRNA in megakaryocytes, develop MF, we investigated whether the TPO axis is hyperactive in this model. Gata1 low mice contained two times more Tpo mRNA in liver and TPO in plasma than wild-type littermates. Furthermore, Gata1 low LSKs expressed levels of Mpl mRNA (five times greater than normal) and protein (two times lower than normal) similar to those expressed by LSKs from TPO-treated wild-type mice. Gata1 low marrow and spleen contained more JAK2/STAT5 than wild-type tissues, an indication that these organs were reach of TPO-responsive cells. Moreover, treatment of Gata1 low mice with the JAK inhibitor ruxolitinib reduced their splenomegaly. Also in Gata1 low mice activation of the TPO/MPL axis was associated with a RSP14 deficiency and a discordant microarray ribosome signature (reduced RPS24, RPS26 and SBDS expression). Finally, electron microscopy revealed that Gata1 low megakaryocytes contained poorly developed endoplasmic reticulum with rare polysomes. In summary, Gata1 low mice are a bona fide model of MF, which recapitulates the hyperactivation of the TPO/MPL/JAK2 axis observed in megakaryocytes from myelofibrotic patients.
INTRODUCTION
A number of studies have shown that the myeloproliferative neoplasm myelofibrosis (MF) is caused by genetic abnormalities involving the thrombopoietin (TPO) axis, including mutations in JAK2, the TPO receptor MPL or in calreticulin (CALR). 1 All three classes of mutations lead to hyperactive JAK/STAT signaling. Furthermore, patients with MF also have elevated serum TPO levels. 2 These mutations, however, are also found in the related myeloproliferative neoplasm diseases polycythemia vera and essential thrombocythemia, prompting the hypothesis that the disease phenotype is determined by a genetic modifier yet to be identified. The observation that MF is specifically associated with reduced GATA1 content in megakaryocytes 3 has suggested that this abnormality may be a phenotypic modifier in MF. The 'element' that specifically links TPO signaling with de-regulated GATA1 expression in megakaryocytes is, therefore, subject of investigation. We have recently presented data suggesting that this 'element' is represented by enrichment of ribosomal pathways gene signatures, which was associated with impaired GATA1 translation in megakaryocytes 4, 5 Support for the role of GATA1 deficiency in megakaryocytes as the 'phenotype modifier' in MF was provided by the observation that mice carrying a hypomorphic mutation (Gata1 low ) that deletes the hypersensitive site (HS1), which drives transcription of Gata1 in megakaryocytes, 6 develop MF. 7 Although Gata1 low mice are not anemic, 7 they are subjected to continuous erythroid stress due to the reduced half-life of their erythrocytes. 8 The animals recover from this stress by activating an alternative erythroid differentiation pathway in the spleen, which involves the production of specific bipotent erythroid/megakaryocyte precursors. 8, 9 The phenotype of the stress precursors identified in Gata1 low mice is different from that identified by Paulson et al., 10 which is induced by acute stress, and is similar to that of the bipotent erythroid/ megakaryocyte precursors generated in vitro by human CD34+ cells in response to a chemical MPL hyperstimulator, 11 leading us to investigate the activation status of the TPO/MPL axis in this model.
MATERIALS AND METHODS Mice
Male wild-type and Gata1 low mice were originally obtained from Dr S Orkin 12 and outbread in the animal facility of Istituto Superiore di Sanità as described. 7, 13 Littermates were genotyped at birth by PCR, 13 and those found not to carry the mutation were used as wild-type controls. Mpl null mice were provided by Dr W Alexander.
14 All the experiments were performed according to the protocols approved by the institutional animal care committee according to the European Directive 86/609/EEC.
Treatments
Bleeding. A volume of 200 μl of blood was collected from wild-type mice through the retro-orbital plexus. Mice were killed by cervical dislocation 24 h later and their tissues removed for further analyses.
TPO treatment. Wild-type mice (9-10 months old) were treated intraperitoneally with of TPO (100 μg/kg/day for 5 days in saline).
Ruxolitinib. Nine-to ten-month-old Gata1 low mice (four males and four females per experimental group) were treated with Ruxolitinib (Rux; #S1378 INCB 018424; Selleckchem, Houston, TX, USA; 45 mg/kg twice per day by gavage in 2% v/v dimethylsulfoxide in H 2 O) and vehicle (2% v/v dimethylsulfoxide in H 2 O) for 5 consecutive days, rested for 2 days and then treated for 5 additional days. 15 On day 17, mice were weighed, bled for blood parameters determinations and killed for organ histopathology observations. Results are compared with those observed in historic wildtype controls. 16, 17 Hematocrit and platelet counts were determined manually.
Flow cytometry and cell sorting
Lineage negative cells were labeled with fluorescein isothiocyanateconjugated Scal, phycoerythrin-conjugated anti-CD117 (cKit) (LSK cells) and anti-MPL antibody (AMM2, Kirin Pharmaceuticals, Tokyo, Japan) 18, 19 or irrelevant isotype-matched antibodies. Cell fluorescence was analyzed with a FACS ARIA cell sorter (Becton Dickinson, Franklin Lakes, NJ, USA) and expressed as mean fluorescent intensity. LSK were isolated as described. 20 Enzyme-linked immunosorbent assay for TPO
The levels of TPO present in platelet-poor plasma and organ washes were measured by enzyme-linked immunosorbent assay (Quantikine Immunoassay mouse TPO; R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer's instructions. Platelet-poor plasma was prepared by centrifugation at 5000 r.p.m.; blood collected with ethylenediaminetetraacetic acid-coated microcapillary tubes (20-40 μl/sampling). Organ washes were prepared as described. 21 
RNA isolation, quantitative reverse transcription-PCR and microarray analyses
Total RNA was prepared with Trizol (Gibco-BRL, Grand Island, NY, USA) and reverse transcribed with random primers using the superscript III kit (Invitrogen Life Technologies, Bethesda, MD, USA). Gene expression levels were quantified by quantitative reverse transcription-PCR using TaqMan Universal PCR Master Mix (Applied Biosystems, Carlsbad, CA, USA) and commercial primers (inventoried TaqMan Gene Expression Assays (Applied Biosystems). GAPDH or β-actin were used as control as described by the manufacturer. Reactions were performed in an ABI 7300 Real Time PCR System (Applied Biosystems). Cycle threshold (Ct) was calculated with the SDS software Version 1.3.1 (Applied Biosystems), and mRNA levels were expressed as 2 − ΔCt (ΔCt = target gene Ct − GAPDH Ct). For microarray analyses, total RNA was extracted from the bone marrow and spleen of 8-to 10-month-old Gata1 low and wild-type littermates and purified with Rneasy Mini Kit (Qiagen, Germantown, MD, USA 
Western blot analysis
Protein extracts separated on SDS-polyacrylamide gel electrophoresis, were blotted on nitrocellulose membranes and probed with antibodies against JAK2 (D2E12 #3230), pSTAT5 (#9351), Ezh2 (Ac22 #3147), SMAD2/3 (#5339), p38 (#9213) and p-p38 (T180/Y182 #4511) (all from Cell Signaling, Boston, MA, USA), STAT5 (#sc-835, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and GAPDH (#CB1001, Calbiochem, San Diego, CA, USA).
Histology
Tissues were fixed in 10% (v/v) phosphate-buffered formalin according to standard procedures, 16 paraffin-embedded and cut into consecutive 2.5-3 μm sections that were then stained either with either hematoxylin-eosin and Gomori silver (MicroStain MicroKit, Bologna, Italy), or immunostained with anti-transforming growth factor (TGF)-β1 (sc-146, Santa Cruz Biotechnology) antibodies. Immunoreactions were detected with STAT-Q Peroxidase-AEC Staining System Kit (Innovex Biosciences, Richmond, CA, USA). Images acquired with the Light microscope (ZEISS, Axioskop, Germany) equipped with a Coolsnap Videocamera were quantified with the MetaMorph 6.1 Software (Universal Imaging Corp., Downingtown, PA, USA). Electron microscopyand immuno-electron microscopy observations were performed as described previously. 16, 17 Statistical analyses
Results were analyzed by analysis of variance (Windows Origin 6.0, Microcal Software Inc., North Hampton, MA, USA), Wilcoxon-MannWhitney test (two-sided) or multi-regression modeling (SAS software v9.2, SAS Institute, Cary, NC, USA). For microarray, Bonferroni-corrected P-values o0.05 were regarded as a statistically significant association. Gene set enrichment analysis was used to identify pathways that were altered in Gata1 low mice as described. 22 
RESULTS

Gata1
low mice express high levels of TPO TPO mRNA was expressed not only, as expected, 23 by the liver and kidney but also by all hematopoietic tissues (spleen, bone marrow and bone) and tissues containing TPO-responsive mast cells (ear, stomach and intestine) 24, 25 both Gata1 low mice and wild-type littermates (Table 1 ). In wild-type mice, the greatest levels of TPO mRNA were detected in the liver (430-fold than any other tissue), followed by kidney and intestine. The liver and stomach from Gata1 low mice expressed levels of TPO mRNA 2-to 3-fold greater than normal while TPO mRNA levels were 10-fold lower than normal in their bone, bone marrow and spleen. This altered pattern of TPO mRNA tissue distribution appears to be unique to Gata1 low mice as bleeding or genetic Mpl ablation had modest effects on the levels of TPO mRNA expressed by tissues from mice wild type at the Gata1 locus. The great levels of TPO mRNA expressed by the liver from Gata1 low mice are consistent with the great levels of interleukin-6, the major regulator of TPO production by the liver, 26 expressed by these mutants.
16
By enzyme-linked immunosorbent assay, TPO protein was detected in the plasma and in washes from all the tissues investigated (bone marrow, spleen, liver and peritoneum; Table 1 ). As expected 27, 28 the greatest levels of TPO protein were detected in the plasma, and these levels were increased by bleeding (by 30%) and Mpl (by threefold) ablation. 29 Also the plasma from Gata1 low mice contained levels of TPO threefold higher than normal (778 ± 101 vs 351 ± 31 pg/ml) and only two times lower than those of the plasma from mice carrying the Mpl null mutation (1287 ± 205 pg/ml; Table 1 ).
The plasma concentration of TPO is mainly regulated by intracellular degradation following binding to its receptor Mpl by megakaryocytes 30 and platelets. 31 The increased production of TPO mRNA by the liver and the greater than normal TPO concentration in the plasma of Gata1 low mice in spite of the numerous megakaryocytes expressing surface levels of MPL two times greater than normal (MPL mean fluorescence intensity~200 vs 600 per wild-type and Gata1 low CD61+CD41+ cells, respectively) present in their bone marrow and spleen indicate that Gata1 low mice contain levels of TPO greatly higher than normal and possibly similar to those reported to induce fatal MF in mice (range 800-8000 pg/ml). 32 In conclusion, Gata1 low mice express high levels of TPO mRNA in the liver and levels of TPO protein in plasma similar to those which induce MF in mice. The thrombopoietin/MPL axis in Gata1 low mice M Zingariello et al their MPL surface expression was two times lower than that of LSK cells from untreated wild-type mice. Similar increments in levels of Mpl mRNA and decrements in levels of MPL cell-surface expression were observed with LSK from wild-type mice subjected to TPO treatment. As with other hematopoietic growth factors, TPO engaging to MPL results in receptor downmodulation followed by activation of de novo gene translation. 33 Therefore, the similarity in the levels of Mpl mRNA and cell-surface protein observed between TPO-treated and Gata1 low LSK indicates that the MPL signaling in LSK from Gata1 low mice is hyperactive. Of note, also CD34+ cells from MF patients express cell-surface MPL levels lower than normal 34 possibly resulting from exposure to TPO levels greater than normal 3 and may indicate pathway hyperactivation as well. 35, 36 Bone marrow and spleen from Gata1 low mice contain levels greater than normal of signaling elements downstream to the TPO and TGF-β signaling To assess the cellular consequences of TPO/MPL activation in Gata1 low mice, the content of its downstream partners JAK2 and STAT5 of bone marrow and spleen from Gata1 low and wild-type littermates was compared by western blot analyses (Figures 2a  and b) . JAK2, STAT5 and pSTAT5 were barely detectable in the bone marrow from wild-type mice but were strikingly elevated in that from the mutant animals. JAK2, and to a lesser extent pSTAT5 staining was also elevated in the spleen from Gata1 low mice. These results suggest that the cellular compartments that respond to TPO are elevated in the bone marrow and spleen from Gata1 low mice. low mice (each lane). GAPDH was used as loading control. Quantification was obtained by normalizing each band to the corresponding GAPDH level and is presented as mean ( ± s.d.) with three mice per experimental group. P-values were determined by analysis of variance (ANOVA). (c, d) Western blot determinations of the SMAD2/3, phosphorylated p38 (p-p38), p38 and EZH2 content in the bone marrow and spleen from wild-type and Gata1 low mice (each line a different mouse). GAPDH was used as a loading control. Quantification was obtained by normalizing p-p38 toward the corresponding p38 band, and SMAD2/3, p38 and EZH2 signals against GAPDH. P-values were calculated by ANOVA. EZH2, enhancer of zeste homolog 2.
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levels of TGF-β greater than normal and an activated TGF-β signaling profile. 37, 38 To compare the cellular alterations induced by TPO and TGF-β activation, the content of elements of the canonical (SMA2/3) and non-canonical (p38) TGF-β signaling, in the bone marrow and spleen from wild-type and Gata1 low littermates was also evaluated (Figures 2c and d) . Gata1 low mice express levels of p38 phosphorylation two times greater than normal in the bone marrow and of SMAD2/3 two times greater than normal in the spleen. Interestingly, the histone-lysine Nmethyltransferase enzyme enhancer of zeste homolog 2, which is part of the polycomb repressive complex 2 subunit activated by nuclear factor-kB downstream to the p38 pathway, 39 was also expressed at levels 410 times greater than normal in the spleen suggesting that although undetected by our analyses, the p38 pathway is also activated in the spleen from Gata1 low mice. Together these results show that the cellular compartments that respond to TPO are mostly expanded in the bone marrow while those that respond to TGF-β are mostly expanded in the spleen from Gata1 low mice.
Rux reduces extramedullary hematopoiesis but does not halt disease progression in Gata1 low mice
The role exerted by JAK2 on the myelofibrotic phenotype expressed by Gata1 low mice was assessed by treating three females and three males with the Food and Drug Administrationapproved JAK inhibitor Rux. Rux also had little effect on the body weight but gave rise to reduced hematocrit and modestly increased platelet counts in the female group (Figures 3a and b) .
The treatment had little effect on the JAK2/STAT5 protein content within the bone marrow (data not shown) and on the STAT5 content of the spleen, but led to a twofold reduction in JAK2 within the spleen (Figure 3c ), suggesting that the treatment had little effects of the cellular composition of the bone marrow but reduced the cells in the spleen, which express JAK2. In agreement with this interpretation, Rux led to a remarkable reduction in spleen size (with respect to both weight and cell number) and restored the splenic architecture both in females and males (Table 2 and Figure 3d ). However, it had no effect on bone marrow cellularity, which remained lower than normal (Table 2) . Rux also had no effect on the frequency of megakaryocytes in the bone marrow, which remained greater than normal, but decreased the frequency of these cells in the spleen (Figures 3d  and e) . Finally, Rux modestly reduced fibrosis in the bone marrow but not in the spleen (Figures 3d and e) . The modest effects exerted by Rux on fibrosis were confirmed by the presence of similar great number of tear drop poikilocytes, that is, reticulocytes with the typical morphological deformation acquired when they pass through fibrotic meshes, observed in blood from vehicle-and Rux-treated mice (data not shown).
We had previously confirmed that in Gata1 low mice altered levels of TGF-β are causative for MF by demonstrating that treatment with an inhibitor of the TGF-β receptor 1 kinase AKL5 Figure 3 . See next page for caption.
The thrombopoietin/MPL axis in Gata1 low mice M Zingariello et al for a duration similar to that investigated here for Rux rescued both their abnormal TGF-β signaling and their myelofibrotic phenotype. 15, 16 To gain insights on the mechanism of action of Rux in this animal model, we investigated the levels of TGF-β in the bone marrow and the spleen of Gata1 low mice treated either with Rux or with vehicle ( Figure 4 ). As expected, 16 by immunohistochemistry both bone marrow and spleen from vehicletreated Gata1 low mice expressed great levels of TGF-β, and the The thrombopoietin/MPL axis in Gata1 low mice M Zingariello et al staining was mainly localized with the megakaryocytes (Figures 4a  and b) . Treatment with Rux decreased by threefold the levels of TGF-β detected in the bone marrow and down to barely detectable in the spleen. The greater effects exerted by Rux on the levels of TGF-β present in the spleen than in the bone marrow are consistent with the fact that this treatment significantly reduced the frequency of megakaryocytes only in the spleen.
In conclusion, these results indicate that Rux rescues the myelofibrotic traits, normalizing the TGF-β of the spleen but is only partially effective in rescuing the defective hematopoiesis of the bone marrow from Gata1 low mice.
Gata1 low mice express a ribosomal signature predictive of ribosomal deficiency We have previously demonstrated that although megakaryocytes from Gata1 low mice contain levels of Gata1 mRNA only twofold lower than normal, the GATA1 protein in these cells is barely detectable. 7, 9 We had attributes this discrepancy to a predicted low sensitivity of immunohistochemistry. However, the demonstration that activation of TPO/MPL/JAK2 signaling induces a ribosomal deficiency within megakaryocytes derived from MF patient stem cells, which hampers GATA1 mRNA translation in ex vivo-expanded megakaryocytes, 5 and the realization that Gata1 low mice express an activated TPO pathway (this manuscript) made us question the original hypothesis that reduced content of GATA1 in Gata1 low megakaryocytes is solely the consequence of deletion of the lineage-specific enhancer. To clarify this point we performed microarray analyses of the bone marrow and the spleen from Gata1 low and wild-type littermates of comparable age (all 10-to 13-month-old males). This analysis identified differential expression of numerous genes between Gata1 low and wild-type littermates. The majority of these genes were in pathways related to inflammation/autoimmunity, including the TGF-β pathway (see GSE89630). Among the differentially expressed genes in the bone marrow, there was a strong discordant ribosome signature, which reached statistical significance for two genes of the large subunit (RLP36AL and RPL27A, both activated in Gata1 low bone marrow) and four genes (RSP6KA1 and RSP9 activated; RSP24 and RSP26 repressed) of the small subunit (Figure 5a ). In addition, there was a significant decline in the mRNA levels for the ribosome maturation protein SBDS, which has been implicated in the joining of the 40S and 60S subunits during the ribosome biogenesis. 40 Of interest, hypomorphic mutations of RSP24 and RSP26 are observed in a subset of patients with Diamond Blackfan anemia, a disease due to inefficient translation of GATA1 mRNA, 41 and loss-of-function mutation of SBDS are associated with the Shwachman-Diamond syndrome, 42 one of the inherited bone marrow failure syndromes with a disease manifestation predictive of ribosomopathy.
A limitation of these results is that they were obtained on mRNA prepared from the entire tissue and therefore were not selective to megakaryocytes. This caveat was addressed by performing a careful electron microscopy study, which confirmed that the cytoplasm of megakaryocytes from Gata1 low mice contain a poorly developed endoplasmic reticulum with rare isolated polysomes, a clear indication of reduced ribosome biogenesis (Figure 5c ).
Next, we used gene set enrichment analysis 22 to identify pathways that are dysregulated in bone marrow and spleen cells of Gata1 low mice. As expected, we observed significant enrichment of a gene set derived from a set of known GATA1 erythroid cell target genes in cells from the bone marrow (Figures 6a and c) . Among other gene sets (Supplementary Table S1 ), we also observed enrichment of the RPS14 gene signature, which was derived from the changes seen upon knockdown of RPS14 in erythroid cells 43 (Figures 6b and d) . In contrast, we did not detect significant changes in ribosome gene mRNA levels (Figure 5b) or downregulation of the RPS14 pathway in the spleen of Gata1 low mice (data not shown). Gene set enrichment analysis further revealed that additional enriched pathways include the cell cycle (including E2F and RB) and transcription, such as GLI1 and HOXA9, the nuclear translocation of which is regulated by TPO 44 (Supplementary Table S1 ).
Together, these results suggest that as observed in the patients, 5 activation of the TPO/MPL pathway, through mechanism(s) still unclear, induces in Gata1 low mice a RSP14 deficiency, which contributes to reduce the GATA1 content in the megakaryocytes of these mice. Reduction of GATA1 content then likely contributes to exacerbate the ribosomal gene defect, perhaps by directly regulating expression of a subset of ribosome genes. Indeed, a recent report showed that GATA1 binds to a subset of ribosome genes, including RPS19 and RPS26. 45 
DISCUSSION
In this manuscript, by showing that Gata1 low mice express a hyperactive TPO/MPL axis, we provide new insights on the mechanism(s) that leads to recovery from chronic anemia, on the differences between regulation of Gata1 in erythroid cells and The thrombopoietin/MPL axis in Gata1 low mice M Zingariello et al megakaryocytes, and on our understanding on how to ameliorate therapies for MF.
Seminal work by Dr Paulson has clarified how the combination of BMP4, soluble stem cell factor and glucocorticoid receptor signaling activates microenvironmental cues in the spleen, which allows recovering from acute stress. 10 By contrast, the mechanisms that lead to recovery from chronic stress, such as those that mediates the expansion of the erythroid compartments in congenic hemoglobinopathies, or during chronic inflammation, are still poorly understood. Studies from the Rivella laboratory had indicated that to recover from chronic anemia, mice, and possibly humans, activate a pathological interaction between erythroblasts and their macrophage niches, which leads to ineffective erythropoiesis. 46 This interaction is restricted by treatment with Rux, indicating that is sustained by JAK signaling activated by unknown cytokines. Also Gata1 low mice suffer from chronic anemia, which is compensated by extramedullary hematopoiesis in the spleen. The data presented in this manuscript suggest that the chronic stress pathway in the spleen is activated by TPO and its downstream JAK-dependent signaling.
The regulatory regions of the Gata1 gene include three hypersensitive sites (HSs). 47 The hypomorphic Gata1 low mutation deletes the distal HS1 sites 12 and reduces by two-to threefold the levels of Gata1 mRNA in the bipotential megakaryocytic/erythroid progenitor cells, in erythroid cells, megakaryocytes and dendritic cells. 20 The mice are born anemic but those that may activate efficiently extramedullary hematopoiesis in the spleen remain thrombocytopenic, recover from anemia soon after birth and have a normal lifespan. 7 As GATA1 is indispensable for erythroid maturation, the question is raised on the mechanisms that rescue erythropoiesis in the spleen of these animals. In addition to HS1, the Gata1 gene contains an additional enhancer HS2. By using a reporter gene driven by HS2, we demonstrated that HS2 is active in erythroid and megakaryocytes from the spleen, but not in those from the bone marrow indicating that activation of mRNA translation from this alternative site may rescue Gata1 deficiency in the spleen. 48 However, although HS2 is active both in erythroid cells and megakaryocytes, erythroid cells from the spleen contain normal levels of GATA1 protein while the levels of GATA1 protein detectable by immunohistochemistry in megakaryocytes remain low. 7, 9 This observation raises the question on the mechanism that reduces the GATA1 protein in the megakaryocytes from the spleen in this mouse model. The microarray analyses described in this paper indicate that the bone marrow, which contains mainly megakaryocytes, express a ribosomal deficiency while the spleen, which contain mainly erythroblasts, does not. In addition, electron microscopy observation indicated that megakaryocytes from both bone marrow and spleen have a poorly developed rough endoplasmic reticulum and contain few ribosomes. These observations suggest that as in myelofibrotic patients, in Gata1 low mice an activated TPO/MPL axis induces a ribosomal deficiency in the megakaryocytes, but not in the erythroid cells, which results in thrombocytopenia due to reduced Gata1 mRNA translation.
MF is the most severe of the Philadelphia chromosomenegative myeloproliferative neoplasms and is characterized by a wide range of constitutional symptoms and short survival. 49 Although a large European study found that the median survival of patients with MF has improved from 4.6 years in 1980-1995 to 6.5 years in 1996-2007, long-term survival of these patients remains low. 50 In 2005, the discovery of the activating JAK2V617F mutation in~50-60% of the patients with MF [51] [52] [53] [54] led to the development of a number of pharmacological inhibitors of Janus Kinases for the treatment of this disease. However, despite the large numbers of JAK inhibitors that were developed and tested for the treatment of MF, only one, Rux, was demonstrated by the large COMFORT clinical trial to markedly improve splenomegaly and MF-associated symptoms over placebo or best available therapy 55, 56 , and has been approved by the Food and Drug Administration for clinical use in this disease. 57 Many other JAK inhibitors have been discontinued or are under consideration for other indications related to chronic inflammation, such as rheumatoid arthritis. 58 However, even Rux has modest effects on bone marrow fibrosis and does not decrease the mutant JAK2 allele burden, 57 leading to questions whether this agent is a truly modifying agent in MF. Although multiple analyses of the Rux trials have shown a survival advantage for Rux -treated patients, 55, 56 it has been argued that the drug may improve survival by improving appetite, weight and correcting cachexia as a result of a robust suppression on inflammatory cytokines some of which have been shown as independent predictors of poor survival in MF. 59 It is currently debated whether Rux may exert some of its functions indirectly, by inhibiting JAK signaling mediated by the pro-inflammatory milieu of the microenvironment.
Although Rux does not affect ALK5 (IC60 = 6907 nM), 60 the TGF-β receptor 1 kinase whose inhibition rescued MF in Gata1 low mice, The thrombopoietin/MPL axis in Gata1 low mice M Zingariello et al treatment with Rux exerted on the phenotype of Gata1 low mice results very similar to those observed in the patients: it reduced spleen size and normalized the cellular architecture of this organ but did not significantly reduced bone marrow fibrosis. Of interest however, it decreased the megakaryocytes and TGF-β content of the spleen, suggesting that it mediates its effects indirectly by normalizing the cellular populations responsible for abnormal TGF-β production in this organ. These results suggest that combination therapy with inhibitors of JAK and TGF-β may be beneficial in the treatment of MF.
In conclusion, these results validate the Gata1 low model as a bona fide model of MF by indicating that these mice express an activated TPO/MPL axis and an abnormal ribosomal signature, which may contribute to reduced expression of GATA1 in megakaryocytes by reducing the efficiency of its mRNA translation.
